iQure Pharma develops therapeutic candidates with a novel mechanisms-of-action for the treatment of epilepsy and neuropathic pain. iQ-007 shows outstanding results in preclinical drug resistant epilepsy models. iQ-008 is a breakthrough multitargeting compound with efficacy superior to Pregabalin (Lyrica, Pfizer). iQ-007 successfully completed NIH Epilepsy screening program and iQ-008 completed Tier 1 NIH Pain screening program.